Prediabetes Management: Lifestyle First, Approved GLP-1 Drugs Where Appropriate, Research Peptides Sidelined

The single most important message for prediabetes is that it is frequently reversible and that the best-evidenced interventions are not research peptides. The foundation is structured lifestyle change: modest weight loss, regular physical activity, reduced refined carbohydrate and calorie intake, better sleep, and reduced alcohol — the same approach used in landmark diabetes-prevention programs, which reduces the chance of progressing to type 2 diabetes. Where medication is considered, metformin has the strongest evidence as a preventive agent in higher-risk individuals, and it is not a peptide. The place approved incretin medicines fit is through weight and appetite: GLP-1 receptor agonists like semaglutide and the dual agonist tirzepatide are approved for weight management and type 2 diabetes, and in people with prediabetes who also qualify (for example, due to obesity), the weight loss and improved insulin sensitivity they produce can move glucose back toward normal — but that is a clinician-guided decision based on approved indications, not a self-assembled 'stack.' Research peptides marketed for 'metabolism,' such as MOTS-c, have preclinical rationales around insulin sensitivity but no controlled human evidence for treating prediabetes, so they should stay out of the plan. In short, build the plan around lifestyle change, add approved medicine under medical guidance where appropriate, and keep unproven peptides on the sidelines.